Kraft Heinz Faces Sequential Q3 Sales Decline as Turnaround Spending Ramps to $700M

What happened

Jefferies maintained a Hold rating and cut its price target to $21, citing expectations that North American retail sales will decline sequentially in the third quarter. The broker attributes the expected decline to weaker consumption and the reversal of a prior inventory benefit, which offset the company's increased investment. Kraft Heinz is ramping up a $700 million turnaround program—slightly larger than the $600 million previously communicated—focused on marketing, R&D, and price-pack architecture. This fresh sequential decline directly challenges management's target of achieving share momentum in the second half of 2026, a key checkpoint for the investment thesis. The news suggests the turnaround is not yet gaining traction, increasing the risk that incremental spending becomes margin dilution rather than volume recovery.

Implication

Investors should note that the stock is already trading near the $21 attractive entry level identified in the master report, so the negative news may be partially priced in. However, the sequential decline in Q3 undermines the base case of volume/mix improving toward zero by that quarter, shifting probability weight toward the bear scenario with an implied value of $18. The increased investment to $700 million, while still funded by strong free cash flow, raises the stakes on execution; if spending fails to convert to units, margin erosion could accelerate. Near-term, the Berkshire overhang and lack of positive volume data are likely to keep sentiment subdued, capping any rerating. We maintain a wait-and-see posture, with a re-assessment after Q3 2026 results confirm whether the revenue decline is stabilizing or accelerating.

Thesis delta

The core thesis—that reinvestment would lead to volume stabilization by H2 2026—faces a setback with Jefferies' expectation of a sequential Q3 retail sales decline. This shifts the risk-reward toward the bear case (implied $18) and reduces confidence in the base case of organic sales near -2% and volume/mix approaching zero. While the stock at ~$21 may already discount much of this, the lack of hard evidence of turnaround progress warrants a more cautious stance until operating results show sequential improvement.